ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

J. Bousquet; O. Pfaar; A. Togias; H. J. Schünemann; I. Ansotegui; N. G. Papadopoulos; I. Tsiligianni; I. Agache; J. M. Anto; C. Bachert; A. Bedbrook; K. C. Bergmann; S. Bosnic-Anticevich; I. Bosse; J. Brozek; M. Calderon; G. W. Canonica; L. Caraballo; V. Cardona; T. Casale; L. Cecchi; D. K. Chu; E. Costa; A. A. Cruz; W. Czarlewski; S. R. Durham; G. Du Toit; M. Dykewicz; M. Ebisawa; J. L. Fauquert; M. Fernandez-Rivas; W. J. Fokkens; J. Fonseca; J. F. Fontaine; R. Gerth Van Wijk; T. Haahtela; S. Halken; P. W. Hellings; D. Ierodiakonou; T. Iinuma; J. C. Ivancevich; L. Jacobsen; M. Jutel; I. Kaidashev; M. Khaitov; O. Kalayci; J. Kleine Tebbe; L. Klimek; M. L. Kowalski; P. Kuna; V. Kvedariene; S. La Grutta; D. Larenas-Linemann; S. Lau; D. Laune; L. Le; K. Lodrup Carlsen; O. Lourenço; H. J. Malling; G. Marien; E. Menditto; G. Mercier; J. Mullol; A. Muraro; R. O'Hehir; Y. Okamoto; G. B. Pajno; H. S. Park; P. Panzner; G. Passalacqua; N. Pham-Thi; G. Roberts; C. Rolland; N. Rosario; D. Ryan; B. Samolinski; M. Sanchez-Borges; G. Scadding; M. H. Shamji; A. Sheikh; G. J. Sturm; A. Todo Bom; S. Toppila-Salmi; M. Valentin-Rostan; A. Valiulis; E. Valovirta; M. T. Ventura; U. Wahn; S. Walker; D. Wallace; S. Waserman; A. Yorgancioglu; T. Zuberbier

doi:10.5414/ALX02096

ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

Translated title of the contribution: 2019 ARIA Care pathways for allergen immunotherapy

J. Bousquet, O. Pfaar, A. Togias, H. J. Schünemann, I. Ansotegui, N. G. Papadopoulos, I. Tsiligianni, I. Agache, J. M. Anto, C. Bachert, A. Bedbrook, K. C. Bergmann, S. Bosnic-Anticevich, I. Bosse, J. Brozek, M. Calderon, G. W. Canonica, L. Caraballo, V. Cardona, T. CasaleL. Cecchi, D. K. Chu, E. Costa, A. A. Cruz, W. Czarlewski, S. R. Durham, G. Du Toit, M. Dykewicz, M. Ebisawa, J. L. Fauquert, M. Fernandez-Rivas, W. J. Fokkens, J. Fonseca, J. F. Fontaine, R. Gerth Van Wijk, T. Haahtela, S. Halken, P. W. Hellings, D. Ierodiakonou, T. Iinuma, J. C. Ivancevich, L. Jacobsen, M. Jutel, I. Kaidashev, M. Khaitov, O. Kalayci, J. Kleine Tebbe, L. Klimek, M. L. Kowalski, P. Kuna, V. Kvedariene, S. La Grutta, D. Larenas-Linemann, S. Lau, D. Laune, L. Le, K. Lodrup Carlsen, O. Lourenço, H. J. Malling, G. Marien, E. Menditto, G. Mercier, J. Mullol, A. Muraro, R. O'Hehir, Y. Okamoto, G. B. Pajno, H. S. Park, P. Panzner, G. Passalacqua, N. Pham-Thi, G. Roberts, C. Rolland, N. Rosario, D. Ryan, B. Samolinski, M. Sanchez-Borges, G. Scadding, M. H. Shamji, A. Sheikh, G. J. Sturm, A. Todo Bom, S. Toppila-Salmi, M. Valentin-Rostan, A. Valiulis, E. Valovirta, M. T. Ventura, U. Wahn, S. Walker, D. Wallace, S. Waserman, A. Yorgancioglu, T. Zuberbier

Research output: Contribution to journal › Review Article › Research › peer-review

2 Citations (Scopus)

Abstract

© 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved. Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.

Translated title of the contribution	2019 ARIA Care pathways for allergen immunotherapy
Original language	German
Pages (from-to)	404-425
Number of pages	22
Journal	Allergologie
Volume	42
Issue number	9
DOIs	https://doi.org/10.5414/ALX02096
Publication status	Published - Sep 2019
Externally published	Yes

Keywords

Allergen immunotherapy
Asthma
Children
MHealth
Rhinitis
Stratification

Access to Document

10.5414/ALX02096

Cite this

Bousquet, J., Pfaar, O., Togias, A., Schünemann, H. J., Ansotegui, I., Papadopoulos, N. G., Tsiligianni, I., Agache, I., Anto, J. M., Bachert, C., Bedbrook, A., Bergmann, K. C., Bosnic-Anticevich, S., Bosse, I., Brozek, J., Calderon, M., Canonica, G. W., Caraballo, L., Cardona, V., ... Zuberbier, T. (2019). ARIA-Versorgungspfade für die Allergenimmuntherapie 2019. Allergologie, 42(9), 404-425. https://doi.org/10.5414/ALX02096

@article{ed1095542cc34f22958069dc015605ad,

title = "ARIA-Versorgungspfade f{\"u}r die Allergenimmuntherapie 2019",

abstract = "{\textcopyright} 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved. Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.",

keywords = "Allergen immunotherapy, Asthma, Children, MHealth, Rhinitis, Stratification",

author = "J. Bousquet and O. Pfaar and A. Togias and Sch{\"u}nemann, {H. J.} and I. Ansotegui and Papadopoulos, {N. G.} and I. Tsiligianni and I. Agache and Anto, {J. M.} and C. Bachert and A. Bedbrook and Bergmann, {K. C.} and S. Bosnic-Anticevich and I. Bosse and J. Brozek and M. Calderon and Canonica, {G. W.} and L. Caraballo and V. Cardona and T. Casale and L. Cecchi and Chu, {D. K.} and E. Costa and Cruz, {A. A.} and W. Czarlewski and Durham, {S. R.} and {Du Toit}, G. and M. Dykewicz and M. Ebisawa and Fauquert, {J. L.} and M. Fernandez-Rivas and Fokkens, {W. J.} and J. Fonseca and Fontaine, {J. F.} and {Gerth Van Wijk}, R. and T. Haahtela and S. Halken and Hellings, {P. W.} and D. Ierodiakonou and T. Iinuma and Ivancevich, {J. C.} and L. Jacobsen and M. Jutel and I. Kaidashev and M. Khaitov and O. Kalayci and {Kleine Tebbe}, J. and L. Klimek and Kowalski, {M. L.} and P. Kuna and V. Kvedariene and {La Grutta}, S. and D. Larenas-Linemann and S. Lau and D. Laune and L. Le and {Lodrup Carlsen}, K. and O. Louren{\c c}o and Malling, {H. J.} and G. Marien and E. Menditto and G. Mercier and J. Mullol and A. Muraro and R. O'Hehir and Y. Okamoto and Pajno, {G. B.} and Park, {H. S.} and P. Panzner and G. Passalacqua and N. Pham-Thi and G. Roberts and C. Rolland and N. Rosario and D. Ryan and B. Samolinski and M. Sanchez-Borges and G. Scadding and Shamji, {M. H.} and A. Sheikh and Sturm, {G. J.} and {Todo Bom}, A. and S. Toppila-Salmi and M. Valentin-Rostan and A. Valiulis and E. Valovirta and Ventura, {M. T.} and U. Wahn and S. Walker and D. Wallace and S. Waserman and A. Yorgancioglu and T. Zuberbier",

year = "2019",

month = sep,

doi = "10.5414/ALX02096",

language = "German",

volume = "42",

pages = "404--425",

journal = "Allergologie",

issn = "0344-5062",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "9",

}

Bousquet, J, Pfaar, O, Togias, A, Schünemann, HJ, Ansotegui, I, Papadopoulos, NG, Tsiligianni, I, Agache, I, Anto, JM, Bachert, C, Bedbrook, A, Bergmann, KC, Bosnic-Anticevich, S, Bosse, I, Brozek, J, Calderon, M, Canonica, GW, Caraballo, L, Cardona, V, Casale, T, Cecchi, L, Chu, DK, Costa, E, Cruz, AA, Czarlewski, W, Durham, SR, Du Toit, G, Dykewicz, M, Ebisawa, M, Fauquert, JL, Fernandez-Rivas, M, Fokkens, WJ, Fonseca, J, Fontaine, JF, Gerth Van Wijk, R, Haahtela, T, Halken, S, Hellings, PW, Ierodiakonou, D, Iinuma, T, Ivancevich, JC, Jacobsen, L, Jutel, M, Kaidashev, I, Khaitov, M, Kalayci, O, Kleine Tebbe, J, Klimek, L, Kowalski, ML, Kuna, P, Kvedariene, V, La Grutta, S, Larenas-Linemann, D, Lau, S, Laune, D, Le, L, Lodrup Carlsen, K, Lourenço, O, Malling, HJ, Marien, G, Menditto, E, Mercier, G, Mullol, J, Muraro, A, O'Hehir, R, Okamoto, Y, Pajno, GB, Park, HS, Panzner, P, Passalacqua, G, Pham-Thi, N, Roberts, G, Rolland, C, Rosario, N, Ryan, D, Samolinski, B, Sanchez-Borges, M, Scadding, G, Shamji, MH, Sheikh, A, Sturm, GJ, Todo Bom, A, Toppila-Salmi, S, Valentin-Rostan, M, Valiulis, A, Valovirta, E, Ventura, MT, Wahn, U, Walker, S, Wallace, D, Waserman, S, Yorgancioglu, A & Zuberbier, T 2019, 'ARIA-Versorgungspfade für die Allergenimmuntherapie 2019', Allergologie, vol. 42, no. 9, pp. 404-425. https://doi.org/10.5414/ALX02096

TY - JOUR

T1 - ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

AU - Bousquet, J.

AU - Pfaar, O.

AU - Togias, A.

AU - Schünemann, H. J.

AU - Ansotegui, I.

AU - Papadopoulos, N. G.

AU - Tsiligianni, I.

AU - Agache, I.

AU - Anto, J. M.

AU - Bachert, C.

AU - Bedbrook, A.

AU - Bergmann, K. C.

AU - Bosnic-Anticevich, S.

AU - Bosse, I.

AU - Brozek, J.

AU - Calderon, M.

AU - Canonica, G. W.

AU - Caraballo, L.

AU - Cardona, V.

AU - Casale, T.

AU - Cecchi, L.

AU - Chu, D. K.

AU - Costa, E.

AU - Cruz, A. A.

AU - Czarlewski, W.

AU - Durham, S. R.

AU - Du Toit, G.

AU - Dykewicz, M.

AU - Ebisawa, M.

AU - Fauquert, J. L.

AU - Fernandez-Rivas, M.

AU - Fokkens, W. J.

AU - Fonseca, J.

AU - Fontaine, J. F.

AU - Gerth Van Wijk, R.

AU - Haahtela, T.

AU - Halken, S.

AU - Hellings, P. W.

AU - Ierodiakonou, D.

AU - Iinuma, T.

AU - Ivancevich, J. C.

AU - Jacobsen, L.

AU - Jutel, M.

AU - Kaidashev, I.

AU - Khaitov, M.

AU - Kalayci, O.

AU - Kleine Tebbe, J.

AU - Klimek, L.

AU - Kowalski, M. L.

AU - Kuna, P.

AU - Kvedariene, V.

AU - La Grutta, S.

AU - Larenas-Linemann, D.

AU - Lau, S.

AU - Laune, D.

AU - Le, L.

AU - Lodrup Carlsen, K.

AU - Lourenço, O.

AU - Malling, H. J.

AU - Marien, G.

AU - Menditto, E.

AU - Mercier, G.

AU - Mullol, J.

AU - Muraro, A.

AU - O'Hehir, R.

AU - Okamoto, Y.

AU - Pajno, G. B.

AU - Park, H. S.

AU - Panzner, P.

AU - Passalacqua, G.

AU - Pham-Thi, N.

AU - Roberts, G.

AU - Rolland, C.

AU - Rosario, N.

AU - Ryan, D.

AU - Samolinski, B.

AU - Sanchez-Borges, M.

AU - Scadding, G.

AU - Shamji, M. H.

AU - Sheikh, A.

AU - Sturm, G. J.

AU - Todo Bom, A.

AU - Toppila-Salmi, S.

AU - Valentin-Rostan, M.

AU - Valiulis, A.

AU - Valovirta, E.

AU - Ventura, M. T.

AU - Wahn, U.

AU - Walker, S.

AU - Wallace, D.

AU - Waserman, S.

AU - Yorgancioglu, A.

AU - Zuberbier, T.

PY - 2019/9

Y1 - 2019/9

N2 - © 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved. Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.

AB - © 2019 Dustri-Verlag Dr. Karl Feistle. All rights reserved. Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence- based method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.

KW - Allergen immunotherapy

KW - Asthma

KW - Children

KW - MHealth

KW - Rhinitis

KW - Stratification

UR - http://www.scopus.com/inward/record.url?scp=85072306392&partnerID=8YFLogxK

U2 - 10.5414/ALX02096

DO - 10.5414/ALX02096

M3 - Review Article

AN - SCOPUS:85072306392

VL - 42

SP - 404

EP - 425

JO - Allergologie

JF - Allergologie

SN - 0344-5062

IS - 9

ER -

ARIA-Versorgungspfade für die Allergenimmuntherapie 2019

Abstract

Keywords

Access to Document

Other files and links

Cite this